Pay in 4 interest-free payments of $7.34 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Endocrine 87 , 951958 (2025)
NHS B12 therapy is evidence-based for documented deficiency, using hydroxocobalamin 1mg intramuscularly with standardised protocols
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Adv Nutr (2019) 10(Suppl1):S49S66
Proc Natl Acad Sci U S A (2003) 100(5):28427
US$ 24.34
US$ 21.70
US$ 21.60
US$ 21.11
US$ 23.97
US$ 28.30
US$ 29.03
US$ 21.17
US$ 22.78
US$ 26.62
